Clinical Trials
7
Active:5
Completed:2
Trial Phases
2 Phases
Phase 1:5
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (71.4%)Phase 2
2 (28.6%)Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)
Phase 2
Completed
- Conditions
- AsthmaChronic Obstructive Pulmonary Disease
- Interventions
- Drug: SelK2 (Part 1)Drug: Placebo (Part 1)Drug: SelK2 (Part 2)Drug: Placebo (Part 2)
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Tetherex Pharmaceuticals Corporation
- Target Recruit Count
- 61
- Registration Number
- NCT04540042
- Locations
- 🇬🇧
Queen Anne Street Medical Centre, London, United Kingdom
🇬🇧Medicines Evaluation Unit Ltd., Manchester, United Kingdom
Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Tetherex Pharmaceuticals Corporation
- Target Recruit Count
- 207
- Registration Number
- NCT03812328
- Locations
- 🇧🇬
UMHAT Kanev AD, Ruse, Bulgaria
🇧🇬Acibadem City Clinic Tokuda Hospital EAD, Sofia, Bulgaria
🇧🇬UMHAT Tsaritsa Yoanna - ISUL, Sofia, Bulgaria
News
No news found